Drugs to treat bacterial infections, malaria, and viruses are losing efficacy to pathogen resistance. The past decade has seen significant investment in new tools like drugs and vaccines but relatively little maintenance of existing tools to protect them. Resistance has emerged to artemisinins, the recommended first-line treatment against malaria in most parts of the world, and has also grown rapidly in the case of antibiotics.
How can the world coordinate to address the threat of depleting drug effectiveness? Who bears the cost of decreasing drug effectiveness? And what will the world look like in 10 to 20 years with and without global efforts to contain resistance?
Mark Cohen is Vice President of Research at Resources For the Future.
Ramanan Laxminarayan is Senior Fellow and Director of the Center for Disease Dynamics, Economics, and Policy at Resources for the Future.
Rachel Nugent is Deputy Director of Global Health at the Center for Global Development.
Kevin Outterson joined the faculty at Boston University Law in Fall 2007. He began teaching as an associate professor of law at West Virginia University in 2002. Before coming to WVU, he was an income partner in the Tax and International groups at McDermott Will & Emery and a capital partner in the Health Law group at Baker Donelson.
He is a graduate of the University of Cambridge (LL.M.) and Northwestern University (B.S. & J.D.). Professor Outterson teaches courses in health care, business law and globalization. His research work focuses on two areas: global pharmaceutical markets and health disparities.